Oppenheimer Maintains Outperform on Q32 Bio, Raises Price Target to $40

Benzinga Newsdesk www.benzinga.com Positive 86.0%

Neg 0% Neu 0% Pos 86%

Oppenheimer analyst Jay Olson maintains Q32 Bio (NASDAQ:QTTB) with a Outperform and raises the price target from $20 to $40.